GSK Unveils GBP275M Investment Plans in UK Manufacturing
The investment will be spread across three sites: Barnard Castle in County Durham; Montrose, Scotland; and Ware, Hertfordshire.
GlaxoSmithKline has announced plans to invest £275 million at three manufacturing sites in the United Kingdom, with the aim of boosting production and supporting the delivery of the company’s respiratory and biopharmaceuticals portfolio. The vast majority of these products will be for export to global markets.
GSK has nine sites employing approximately 6000 staff in the UK. According to the pharmaceutical firm, UK is an attractive location for investment in advanced manufacturing driven by the skilled workforce, technological and scientific capabilities and infrastructure, and a competitive corporate tax system. The Patent Box, for example, encourages investment in R&D and related manufacturing in the UK by delivering a lower rate of corporation tax on profits generated from UK-owned intellectual property.
The investment will be split across three UK sites:
- £92 million will be used to fund the construction of an aseptic sterile facility at Barnard Castle in County Durham, for the manufacture of existing and new biopharmaceutical assets. This site is one of GSK’s biggest secondary manufacturing sites, supplying nearly half a million packs of products per day to 140 global markets.
- Approximately £110 million will be invested in a new, state-of-the-art facility for the manufacture of respiratory active ingredients in Montrose in Angus in Scotland. This site manufactures APIs for respiratory, HIV, and vaccine products.
- £74 million will be used to expand the manufacturing capacity of GSK’s new Ellipta respiratory inhaler in Ware, Hertfordshire. This site manufactures respiratory products.
It is expected that with the construction of these new facilities in place, GSK will lead in the creation of new employment opportunities.
Source: GSK
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
